# A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

> **NCT05280275** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Hellenic Society of Hematology** · enrollment: 36 (estimated)

## Conditions studied

- Multiple Myeloma
- Neoplasms
- Neoplasms, Plasma Cell
- Gammopathy, Monoclonal
- Paraproteinemias
- Blood Protein Disorders
- Haematologic Disease
- Corneal Disease

## Interventions

- **DRUG:** Belantamab Mafodotin-Blmf
- **DRUG:** Daratumumab
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05280275
- **Lead sponsor:** Hellenic Society of Hematology
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-13
- **Primary completion:** 2026-03-15
- **Final completion:** 2026-03-15
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2023-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05280275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05280275, "A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05280275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*